Visual Outcomes and Quality of Life After Vivity EDOF IOL Implantation in Early-Stage Keratoconus
NCT ID: NCT07338708
Last Updated: 2026-01-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
10 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-09-17
Study Completion Date
2025-05-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to learn if the Vivity Extended Depth of Focus intraocular lens works to improve vision in adults with cataracts and early-stage keratoconus. It will also learn about the safety and tolerance of this premium lens in patients with mild corneal irregularities. The main questions it aims to answer are:
* Does the Vivity EDOF lens provide good distance vision (20/25 or better) in the dominant eye at 3 months after surgery?
* Does it improve vision at intermediate and near distances compared to before surgery?
* Does it preserve contrast sensitivity and optical quality despite mild corneal irregularities?
* What is the patient-reported quality of life and satisfaction after implantation?
* What visual disturbances (such as halos) do participants experience?
All participants will:
* Receive the Vivity EDOF intraocular lens (or its toric version if astigmatism is present) in both eyes during standard cataract surgery, with the second eye operated within 7 days;
* Undergo comprehensive eye examinations before surgery including vision testing, corneal imaging, and optical quality measurements;
* Attend a follow-up visit at 3 months after surgery for detailed vision testing at multiple distances, contrast sensitivity testing under different lighting conditions, halo assessment, and quality-of-life questionnaires.
* Does the Vivity EDOF lens provide good distance vision (20/25 or better) in the dominant eye at 3 months after surgery?
* Does it improve vision at intermediate and near distances compared to before surgery?
* Does it preserve contrast sensitivity and optical quality despite mild corneal irregularities?
* What is the patient-reported quality of life and satisfaction after implantation?
* What visual disturbances (such as halos) do participants experience?
All participants will:
* Receive the Vivity EDOF intraocular lens (or its toric version if astigmatism is present) in both eyes during standard cataract surgery, with the second eye operated within 7 days;
* Undergo comprehensive eye examinations before surgery including vision testing, corneal imaging, and optical quality measurements;
* Attend a follow-up visit at 3 months after surgery for detailed vision testing at multiple distances, contrast sensitivity testing under different lighting conditions, halo assessment, and quality-of-life questionnaires.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Head-to-Head Comparison of Five Enhanced Depth of Focus IOLs and One Monofocal IOL
NCT07051720
Cataract and IOL Surgery
IOL Implantation
Presbyopia Correction
+1 more
RECRUITING
NA
Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
NCT04098367
Aphakia
COMPLETED
NA
Reading Performance in Patients With Acrysof IQ Vivity Versus Acrysof IQ
NCT05194657
Cataract
UNKNOWN
NA
A Clinical Study of the ACRYSOF® IQ Extended Depth of Focus Intraocular Lens (IOL)
NCT03274986
Cataract
COMPLETED
NA
PMCF Study on Comparison of EDOF Lenses (Switzerland)
NCT05235139
Cataract
Lens Opacities
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background and Rationale Keratoconus (KC) is a progressive, non-inflammatory corneal ectasia characterized by stromal thinning and irregular astigmatism, often resulting in significant higher-order aberrations (HOAs) that impair visual quality. Due to these optical limitations, the use of premium intraocular lenses (pIOLs) has traditionally been considered contraindicated in these patients. However, in patients with early-stage keratoconus, corneal shape and optical quality can be relatively well preserved, with HOAs remaining within acceptable limits. These patients may thus benefit from carefully selected premium IOL technologies.
Extended-depth-of-focus (EDOF) IOLs, in contrast to traditional multifocal lenses, not only provide significantly fewer visual disturbances but, thanks to their elongated focus, they could mitigate HOAs and coma-like distortions characteristic of early keratoconus. Unlike monofocal or multifocal lenses, which rely on a single, sharp focal point or discrete focal planes, EDOF lenses are inherently designed to maintain functional retinal image quality across an extended focal range, offering greater tolerance to minor defocus and wavefront aberrations. While EDOF lenses do not correct such aberrations, their extended focal range may reduce the impact of this distortion on functional vision. This is especially true for non-diffractive EDOF lenses, which preserve high levels of contrast sensitivity by not splitting light energy into multiple focal points.
The AcrySof IQ Vivity IOL (Alcon, Fort Worth, TX, USA) is a non-diffractive EDOF IOL that uses wavefront-shaping technology to elongate the focal range. Previous studies have already demonstrated good outcomes in patients with other challenging ocular conditions such as glaucoma, macular degeneration, and epiretinal membrane. The present pilot study aims to evaluate the visual performance, tolerance, and optical quality outcomes following implantation of the Vivity IOL in patients with cataract and stable, early-stage keratoconus. This investigation explores the clinical viability of premium IOLs in a population traditionally excluded from such refractive options.
Study Design This is a prospective, interventional, single-center pilot study conducted in Italy. The study has been approved by the local ethics committee (protocol number 22546) and adheres to the principles of the Declaration of Helsinki. A total of 10 patients (20 eyes) with cataracts and mild bilateral keratoconus will be enrolled and followed for 3 months after bilateral implantation of the AcrySof IQ Vivity EDOF IOL.
Study Objectives
Primary Objective:
\- To evaluate monocular distance-corrected visual acuity (DCVA) in the dominant eye at 3 months after surgery.
Secondary Objectives:
* To assess monocular and binocular uncorrected and distance-corrected visual acuity at distance (4 meters), intermediate (66 cm), and near (40 cm)
* To evaluate binocular defocus curves from +1.50 D to -3.50 D in 0.50 D increments;
* To measure monocular and binocular contrast sensitivity under photopic (80 cd/m²), mesopic (6 cd/m²), and scotopic (3 cd/m²) lighting conditions;
* To assess ocular optical quality including root mean square (RMS) wavefront error and point spread function (PSF) Strehl ratio at 3 mm and 4 mm pupil diameters;
* To evaluate binocular halo perception using standardized halometry;
* To assess patient-reported quality of life using the National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL-42) questionnaire;
* To evaluate the safety profile including intra- and postoperative complications and adverse events;
* To assess toric IOL rotational stability in eyes receiving the toric version.
Eligibility criteria such as inclusion and exclusion criteria are reported separately.
Preoperative Assessment:
All patients will receive a comprehensive ophthalmologic evaluation prior to surgery, including:
* Measurement of monocular and binocular uncorrected and corrected visual acuity for distance (4 meters) and near (40 cm) using CSO Vision Charts software version 14.0
* Corneal tomography using MS-39 anterior segment optical coherence tomography (CSO, Florence, Italy)
* Ocular optical quality analysis using Pyramidal WaveFront-based sensor aberrometer (Osiris T Aberrometer, CSO, Florence, Italy) to assess higher-order aberrations including coma and coma-like aberrations
* Optical biometry using Lenstar 900 (Haag-Streit Diagnostics, Koeniz, Switzerland) for axial length and IOL power calculation
* Intraocular pressure measurement
* Slit-lamp examination of the anterior segment
* Dilated fundoscopy
* Macular evaluation through spectral-domain optical coherence tomography (Spectralis OCT, Heidelberg Engineering GmbH, Germany)
* Ocular dominance determination using the Miles test
Surgical Procedure:
All patients will undergo standard phacoemulsification cataract surgery performed by the same experienced surgeon using a 2.2 mm phaco probe under topical anesthesia. The AcrySof IQ Vivity EDOF IOL will be implanted in the capsular bag with a target of emmetropia bilaterally. IOL power calculation will be performed using the Kane formula. In eyes with regular corneal astigmatism equal to or greater than 1.00 diopter, the toric version of the Vivity IOL (AcrySof IQ Vivity Toric) will be implanted to optimize postoperative refractive outcomes. The second eye will be operated within 7 days of the first eye surgery.
Postoperative Follow-up:
Toric IOL rotational stability will be assessed on postoperative days 1 and 7 to account for early positional shifts and to allow for re-centering if necessary. The IOL will be deemed stable if the angular deviation is less than 5 degrees and if it induces a residual cylindrical error of 0.75 diopters or less, as estimated using the Toric IOL Assistant feature of the Osiris T Aberrometer.
Complete ophthalmological examination will be performed at the 3-month follow-up visit and outcome measures are measured as explained in the outcome measures section.
The Vivity IOL Technology The AcrySof IQ Vivity is a single-piece, hydrophobic acrylic EDOF IOL that utilizes a non-diffractive wavefront-shaping mechanism to enhance intermediate and near vision. The optic is 6.0 mm in diameter with an overall length of 13.0 mm and features a C-loop haptic design. The lens material incorporates both ultraviolet and blue light-filtering chromophores and has a refractive index of 1.55 at 35°C.
The lens design is based on a monofocal aspheric platform with an aberration-neutral anterior surface. The central optical zone incorporates X-WAVE technology, which integrates two subtle anterior surface transition elements: a slightly elevated central plateau (approximately 1 micrometer) that stretches the wavefront to extend the focus, and a surrounding curvature modulation that shifts the wavefront, ensuring efficient retinal energy delivery across the extended range.
The spherical model is available in powers ranging from +15.0 diopters to +25.0 diopters in 0.5 diopter increments, with additional availability up to +30.0 diopters in selected markets. The toric version, AcrySof IQ Vivity Toric, incorporates the same non-diffractive EDOF design and is offered in cylinder powers from 1.03 diopters to 4.11 diopters at the IOL plane.
Statistical Analysis All statistical analyses will be performed using STATA software, version 13.0 (StataCorp, College Station, TX, USA). The distribution of continuous variables will be assessed with the Shapiro-Wilk test. When data are normally distributed, results will be reported as mean ± standard deviation.
To evaluate the safety profile of the implanted IOL, both absolute and relative frequencies of intra- and postoperative complications, as well as any adverse events, will be recorded and analyzed at each follow-up. Paired t-tests will be conducted between preoperative and postoperative DCVA, DCNVA, UDVA, UNVA, and total RMS to assess postoperative functional improvement.
The primary endpoint is the evaluation of DCVA in the dominant eye at 3 months. A formal sample-size calculation was performed based on a previous pilot series reporting a standard deviation of 0.01 logMAR for monocular DCVA in eyes with stable keratoconus and cataract implanted with a premium IOL. A single-group design was used to estimate a 95% confidence interval for one standard deviation via the chi-square method. Assuming a standard deviation of 0.017 logMAR, 10 subjects (10 eyes) are required to yield a confidence interval half-width no greater than 0.02 logMAR (equivalent to one ETDRS letter). Sample-size calculations were carried out with PASS 2023, version 23.0.2.
Safety Considerations All participants will be carefully monitored for any adverse events or complications related to the surgical procedure or the implanted IOL. Standard cataract surgery risks include infection (endophthalmitis), inflammation, bleeding, increased intraocular pressure, lens dislocation, posterior capsule rupture, cystoid macular edema, and retinal detachment. Additional considerations specific to premium IOLs include the potential for visual disturbances such as glare, halos, starbursts, reduced contrast sensitivity, and in rare cases, dissatisfaction requiring IOL exchange.
In the specific context of keratoconus patients, there is theoretical concern that residual corneal irregularities and higher-order aberrations might interact with the IOL optics in unpredictable ways, potentially limiting visual quality or increasing photic phenomena. However, by carefully selecting only patients with early-stage, stable keratoconus and relatively preserved corneal morphology, this study aims to minimize these risks while exploring the potential benefits of EDOF technology in this population.
Any serious adverse events will be immediately reported to the ethics committee and appropriate medical management will be provided. Participants are free to withdraw from the study at any time without affecting their medical care.
Expected Outcomes and Significance This pilot study will provide preliminary evidence regarding the safety, efficacy, and patient satisfaction associated with Vivity EDOF IOL implantation in patients with early-stage keratoconus. If successful, the results may challenge the traditional view that premium IOLs are contraindicated in keratoconus and open new treatment options for carefully selected patients who wish to reduce spectacle dependence after cataract surgery.
The non-diffractive EDOF design of the Vivity lens, with its extended focal range and preserved contrast sensitivity, may be particularly well-suited to tolerating the mild corneal irregularities present in early keratoconus. By extending the depth of focus rather than creating discrete focal points, the lens may maintain functional vision despite minor wavefront aberrations.
Results from this study will inform larger, multicenter, randomized controlled trials and may ultimately contribute to updated clinical guidelines for IOL selection in keratoconus patients
Extended-depth-of-focus (EDOF) IOLs, in contrast to traditional multifocal lenses, not only provide significantly fewer visual disturbances but, thanks to their elongated focus, they could mitigate HOAs and coma-like distortions characteristic of early keratoconus. Unlike monofocal or multifocal lenses, which rely on a single, sharp focal point or discrete focal planes, EDOF lenses are inherently designed to maintain functional retinal image quality across an extended focal range, offering greater tolerance to minor defocus and wavefront aberrations. While EDOF lenses do not correct such aberrations, their extended focal range may reduce the impact of this distortion on functional vision. This is especially true for non-diffractive EDOF lenses, which preserve high levels of contrast sensitivity by not splitting light energy into multiple focal points.
The AcrySof IQ Vivity IOL (Alcon, Fort Worth, TX, USA) is a non-diffractive EDOF IOL that uses wavefront-shaping technology to elongate the focal range. Previous studies have already demonstrated good outcomes in patients with other challenging ocular conditions such as glaucoma, macular degeneration, and epiretinal membrane. The present pilot study aims to evaluate the visual performance, tolerance, and optical quality outcomes following implantation of the Vivity IOL in patients with cataract and stable, early-stage keratoconus. This investigation explores the clinical viability of premium IOLs in a population traditionally excluded from such refractive options.
Study Design This is a prospective, interventional, single-center pilot study conducted in Italy. The study has been approved by the local ethics committee (protocol number 22546) and adheres to the principles of the Declaration of Helsinki. A total of 10 patients (20 eyes) with cataracts and mild bilateral keratoconus will be enrolled and followed for 3 months after bilateral implantation of the AcrySof IQ Vivity EDOF IOL.
Study Objectives
Primary Objective:
\- To evaluate monocular distance-corrected visual acuity (DCVA) in the dominant eye at 3 months after surgery.
Secondary Objectives:
* To assess monocular and binocular uncorrected and distance-corrected visual acuity at distance (4 meters), intermediate (66 cm), and near (40 cm)
* To evaluate binocular defocus curves from +1.50 D to -3.50 D in 0.50 D increments;
* To measure monocular and binocular contrast sensitivity under photopic (80 cd/m²), mesopic (6 cd/m²), and scotopic (3 cd/m²) lighting conditions;
* To assess ocular optical quality including root mean square (RMS) wavefront error and point spread function (PSF) Strehl ratio at 3 mm and 4 mm pupil diameters;
* To evaluate binocular halo perception using standardized halometry;
* To assess patient-reported quality of life using the National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL-42) questionnaire;
* To evaluate the safety profile including intra- and postoperative complications and adverse events;
* To assess toric IOL rotational stability in eyes receiving the toric version.
Eligibility criteria such as inclusion and exclusion criteria are reported separately.
Preoperative Assessment:
All patients will receive a comprehensive ophthalmologic evaluation prior to surgery, including:
* Measurement of monocular and binocular uncorrected and corrected visual acuity for distance (4 meters) and near (40 cm) using CSO Vision Charts software version 14.0
* Corneal tomography using MS-39 anterior segment optical coherence tomography (CSO, Florence, Italy)
* Ocular optical quality analysis using Pyramidal WaveFront-based sensor aberrometer (Osiris T Aberrometer, CSO, Florence, Italy) to assess higher-order aberrations including coma and coma-like aberrations
* Optical biometry using Lenstar 900 (Haag-Streit Diagnostics, Koeniz, Switzerland) for axial length and IOL power calculation
* Intraocular pressure measurement
* Slit-lamp examination of the anterior segment
* Dilated fundoscopy
* Macular evaluation through spectral-domain optical coherence tomography (Spectralis OCT, Heidelberg Engineering GmbH, Germany)
* Ocular dominance determination using the Miles test
Surgical Procedure:
All patients will undergo standard phacoemulsification cataract surgery performed by the same experienced surgeon using a 2.2 mm phaco probe under topical anesthesia. The AcrySof IQ Vivity EDOF IOL will be implanted in the capsular bag with a target of emmetropia bilaterally. IOL power calculation will be performed using the Kane formula. In eyes with regular corneal astigmatism equal to or greater than 1.00 diopter, the toric version of the Vivity IOL (AcrySof IQ Vivity Toric) will be implanted to optimize postoperative refractive outcomes. The second eye will be operated within 7 days of the first eye surgery.
Postoperative Follow-up:
Toric IOL rotational stability will be assessed on postoperative days 1 and 7 to account for early positional shifts and to allow for re-centering if necessary. The IOL will be deemed stable if the angular deviation is less than 5 degrees and if it induces a residual cylindrical error of 0.75 diopters or less, as estimated using the Toric IOL Assistant feature of the Osiris T Aberrometer.
Complete ophthalmological examination will be performed at the 3-month follow-up visit and outcome measures are measured as explained in the outcome measures section.
The Vivity IOL Technology The AcrySof IQ Vivity is a single-piece, hydrophobic acrylic EDOF IOL that utilizes a non-diffractive wavefront-shaping mechanism to enhance intermediate and near vision. The optic is 6.0 mm in diameter with an overall length of 13.0 mm and features a C-loop haptic design. The lens material incorporates both ultraviolet and blue light-filtering chromophores and has a refractive index of 1.55 at 35°C.
The lens design is based on a monofocal aspheric platform with an aberration-neutral anterior surface. The central optical zone incorporates X-WAVE technology, which integrates two subtle anterior surface transition elements: a slightly elevated central plateau (approximately 1 micrometer) that stretches the wavefront to extend the focus, and a surrounding curvature modulation that shifts the wavefront, ensuring efficient retinal energy delivery across the extended range.
The spherical model is available in powers ranging from +15.0 diopters to +25.0 diopters in 0.5 diopter increments, with additional availability up to +30.0 diopters in selected markets. The toric version, AcrySof IQ Vivity Toric, incorporates the same non-diffractive EDOF design and is offered in cylinder powers from 1.03 diopters to 4.11 diopters at the IOL plane.
Statistical Analysis All statistical analyses will be performed using STATA software, version 13.0 (StataCorp, College Station, TX, USA). The distribution of continuous variables will be assessed with the Shapiro-Wilk test. When data are normally distributed, results will be reported as mean ± standard deviation.
To evaluate the safety profile of the implanted IOL, both absolute and relative frequencies of intra- and postoperative complications, as well as any adverse events, will be recorded and analyzed at each follow-up. Paired t-tests will be conducted between preoperative and postoperative DCVA, DCNVA, UDVA, UNVA, and total RMS to assess postoperative functional improvement.
The primary endpoint is the evaluation of DCVA in the dominant eye at 3 months. A formal sample-size calculation was performed based on a previous pilot series reporting a standard deviation of 0.01 logMAR for monocular DCVA in eyes with stable keratoconus and cataract implanted with a premium IOL. A single-group design was used to estimate a 95% confidence interval for one standard deviation via the chi-square method. Assuming a standard deviation of 0.017 logMAR, 10 subjects (10 eyes) are required to yield a confidence interval half-width no greater than 0.02 logMAR (equivalent to one ETDRS letter). Sample-size calculations were carried out with PASS 2023, version 23.0.2.
Safety Considerations All participants will be carefully monitored for any adverse events or complications related to the surgical procedure or the implanted IOL. Standard cataract surgery risks include infection (endophthalmitis), inflammation, bleeding, increased intraocular pressure, lens dislocation, posterior capsule rupture, cystoid macular edema, and retinal detachment. Additional considerations specific to premium IOLs include the potential for visual disturbances such as glare, halos, starbursts, reduced contrast sensitivity, and in rare cases, dissatisfaction requiring IOL exchange.
In the specific context of keratoconus patients, there is theoretical concern that residual corneal irregularities and higher-order aberrations might interact with the IOL optics in unpredictable ways, potentially limiting visual quality or increasing photic phenomena. However, by carefully selecting only patients with early-stage, stable keratoconus and relatively preserved corneal morphology, this study aims to minimize these risks while exploring the potential benefits of EDOF technology in this population.
Any serious adverse events will be immediately reported to the ethics committee and appropriate medical management will be provided. Participants are free to withdraw from the study at any time without affecting their medical care.
Expected Outcomes and Significance This pilot study will provide preliminary evidence regarding the safety, efficacy, and patient satisfaction associated with Vivity EDOF IOL implantation in patients with early-stage keratoconus. If successful, the results may challenge the traditional view that premium IOLs are contraindicated in keratoconus and open new treatment options for carefully selected patients who wish to reduce spectacle dependence after cataract surgery.
The non-diffractive EDOF design of the Vivity lens, with its extended focal range and preserved contrast sensitivity, may be particularly well-suited to tolerating the mild corneal irregularities present in early keratoconus. By extending the depth of focus rather than creating discrete focal points, the lens may maintain functional vision despite minor wavefront aberrations.
Results from this study will inform larger, multicenter, randomized controlled trials and may ultimately contribute to updated clinical guidelines for IOL selection in keratoconus patients
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cataract
Keratoconic Subjects
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
This is a single-arm, prospective pilot study evaluating bilateral implantation of the AcrySof IQ Vivity Extended Depth of Focus (EDOF) intraocular lens (IOL) in patients with cataracts and early-stage, stable keratoconus. All participants receive the same intervention (Vivity EDOF IOL in both eyes, or its toric version if corneal astigmatism ≥1.00 D is present), with surgery on the second eye performed within 7 days of the first. There is no control or comparison group. The study explores whether this non-diffractive EDOF technology, which uses wavefront-shaping to extend focal range while preserving contrast sensitivity, can safely provide functional vision at multiple distances in a population (early keratoconus) traditionally considered unsuitable for premium IOLs due to corneal irregularities and higher-order aberrations. Outcomes are assessed at 3 months postoperatively.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vivity EDOF IOL in Early Keratoconus
Adults with cataracts and mild, stable bilateral keratoconus (ABCD stage 0-1) undergo bilateral implantation of the AcrySof IQ Vivity Extended Depth of Focus (EDOF) intraocular lens during standard phacoemulsification cataract surgery. The toric version is used in eyes with regular corneal astigmatism ≥1.00 D. Surgery is performed under topical anesthesia by the same surgeon, targeting bilateral emmetropia using Kane formula for IOL power calculation. The second eye is operated within 7 days of the first. The Vivity IOL is a non-diffractive EDOF lens utilizing X-WAVE wavefront-shaping technology to extend focal range without splitting light, designed to reduce visual disturbances while providing functional vision at distance, intermediate (66 cm), and near (40 cm). Comprehensive visual, optical quality, contrast sensitivity, and patient-reported outcomes are assessed at 3 months postoperatively
Group Type
EXPERIMENTAL
Extended Depth of Focus Intraocular Lens Implantation
Intervention Type
DEVICE
Bilateral implantation of the AcrySof IQ Vivity (Alcon, Fort Worth, TX, USA) Extended Depth of Focus (EDOF) intraocular lens during phacoemulsification cataract surgery. The Vivity is a single-piece hydrophobic acrylic IOL (6.0 mm optic, 13.0 mm overall length) featuring non-diffractive X-WAVE wavefront-shaping technology with a slightly elevated central plateau (\~1 µm) and surrounding curvature modulation to extend focal range. It incorporates UV and blue light filtering with refractive index 1.55 at 35°C. The spherical model (powers +15.0 D to +25.0 D) or toric model (cylinder 1.03 D to 4.11 D at IOL plane) is selected based on corneal astigmatism. IOL power calculated using Kane formula targeting emmetropia. Surgery performed with 2.2 mm incision under topical anesthesia, with second-eye surgery within 7 days. This study specifically evaluates performance in patients with early-stage stable keratoconus.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extended Depth of Focus Intraocular Lens Implantation
Bilateral implantation of the AcrySof IQ Vivity (Alcon, Fort Worth, TX, USA) Extended Depth of Focus (EDOF) intraocular lens during phacoemulsification cataract surgery. The Vivity is a single-piece hydrophobic acrylic IOL (6.0 mm optic, 13.0 mm overall length) featuring non-diffractive X-WAVE wavefront-shaping technology with a slightly elevated central plateau (\~1 µm) and surrounding curvature modulation to extend focal range. It incorporates UV and blue light filtering with refractive index 1.55 at 35°C. The spherical model (powers +15.0 D to +25.0 D) or toric model (cylinder 1.03 D to 4.11 D at IOL plane) is selected based on corneal astigmatism. IOL power calculated using Kane formula targeting emmetropia. Surgery performed with 2.2 mm incision under topical anesthesia, with second-eye surgery within 7 days. This study specifically evaluates performance in patients with early-stage stable keratoconus.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults requiring bilateral cataract surgery
* Mild bilateral keratoconus defined as stage 0-1 according to the ABCD classification system
* Keratoconus stability defined as maximum keratometry (K) changes less than 1 diopter and maximum pachymetry reduction less than 2% within the previous 5 years
* Pre-cataract spectacle distance-corrected visual acuity of 0.1 to 0.0 LogMAR (Snellen 20/25 to 20/20)
* Agreement to bilateral implantation of AcrySof IQ Vivity Extended Depth of Focus intraocular lens
* Willingness to undergo second-eye surgery within 7 days after first-eye procedure
* Ability and willingness to attend all scheduled follow-up visits as per study protocol
* Provision of written informed consent to participate in the study
* Mild bilateral keratoconus defined as stage 0-1 according to the ABCD classification system
* Keratoconus stability defined as maximum keratometry (K) changes less than 1 diopter and maximum pachymetry reduction less than 2% within the previous 5 years
* Pre-cataract spectacle distance-corrected visual acuity of 0.1 to 0.0 LogMAR (Snellen 20/25 to 20/20)
* Agreement to bilateral implantation of AcrySof IQ Vivity Extended Depth of Focus intraocular lens
* Willingness to undergo second-eye surgery within 7 days after first-eye procedure
* Ability and willingness to attend all scheduled follow-up visits as per study protocol
* Provision of written informed consent to participate in the study
Exclusion Criteria
* Any ocular comorbidities other than cataract and keratoconus, or history of any disease that could affect visual results (e.g., glaucoma, retinal disorders)
* Corneal opacity including any corneal scarring
* Advanced or progressive keratoconus
* Any previous ocular surgery other than corneal cross-linking performed at least 5 years prior to enrollment
* Corneal cross-linking performed within 5 years prior to enrollment
* Amblyopia
* Pseudoexfoliation syndrome or zonular laxity
* History of uveitis
* Corneal opacity including any corneal scarring
* Advanced or progressive keratoconus
* Any previous ocular surgery other than corneal cross-linking performed at least 5 years prior to enrollment
* Corneal cross-linking performed within 5 years prior to enrollment
* Amblyopia
* Pseudoexfoliation syndrome or zonular laxity
* History of uveitis
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera Universitaria Integrata Verona
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emilio Pedrotti
Full Professor in Ophthalmology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera Integrata di Verona
Verona, Verona, Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Farideh D, Azad S, Feizollah N, Sana N, Cyrus A, Mohammad G, Alireza BR. Clinical outcomes of new toric trifocal diffractive intraocular lens in patients with cataract and stable keratoconus: Six months follow-up. Medicine (Baltimore). 2017 Mar;96(12):e6340. doi: 10.1097/MD.0000000000006340.
Reference Type
BACKGROUND
Rampat R, Gatinel D. Multifocal and Extended Depth-of-Focus Intraocular Lenses in 2020. Ophthalmology. 2021 Nov;128(11):e164-e185. doi: 10.1016/j.ophtha.2020.09.026. Epub 2020 Sep 25.
Reference Type
BACKGROUND
Pedrotti E, Chierego C, Talli PM, Selvi F, Galzignato A, Neri E, Barosco G, Montresor A, Rodella A, Marchini G. Extended Depth of Focus Versus Monofocal IOLs: Objective and Subjective Visual Outcomes. J Refract Surg. 2020 Apr 1;36(4):214-222. doi: 10.3928/1081597X-20200212-01.
Reference Type
BACKGROUND
Palomino-Bautista C, Sanchez-Jean R, Carmona-Gonzalez D, Pinero DP, Molina-Martin A. Subjective and objective depth of field measures in pseudophakic eyes: comparison between extended depth of focus, trifocal and bifocal intraocular lenses. Int Ophthalmol. 2020 Feb;40(2):351-359. doi: 10.1007/s10792-019-01186-6. Epub 2019 Oct 3.
Reference Type
BACKGROUND
Gillmann K, Mermoud A. Visual Performance, Subjective Satisfaction and Quality of Life Effect of a New Refractive Intraocular Lens with Central Extended Depth of Focus. Klin Monbl Augenheilkd. 2019 Apr;236(4):384-390. doi: 10.1055/a-0799-9700. Epub 2019 Feb 14.
Reference Type
BACKGROUND
Pedrotti E, Mastropasqua R, Passilongo M, Parisi G, Marchesoni I, Marchini G. Comparison of two multifocal intraocular lens designs that differ only in near add. J Refract Surg. 2014 Nov;30(11):754-60. doi: 10.3928/1081597X-20141021-07.
Reference Type
BACKGROUND
Alio JL, Pinero DP, Plaza-Puche AB, Amparo F, Jimenez R, Rodriguez-Prats JL, Javaloy J. Visual and optical performance with two different diffractive multifocal intraocular lenses compared to a monofocal lens. J Refract Surg. 2011 Aug;27(8):570-81. doi: 10.3928/1081597X-20101223-01. Epub 2011 Jan 3.
Reference Type
BACKGROUND
Gil MA, Varon C, Cardona G, Vega F, Buil JA. Comparison of far and near contrast sensitivity in patients symmetrically implanted with multifocal and monofocal IOLs. Eur J Ophthalmol. 2014 Jan-Feb;24(1):44-52. doi: 10.5301/ejo.5000335. Epub 2013 Jun 24.
Reference Type
BACKGROUND
Buckhurst PJ, Naroo SA, Davies LN, Shah S, Drew T, Wolffsohn JS. Assessment of dysphotopsia in pseudophakic subjects with multifocal intraocular lenses. BMJ Open Ophthalmol. 2017 Jun 19;1(1):e000064. doi: 10.1136/bmjophth-2016-000064. eCollection 2017.
Reference Type
BACKGROUND
de Silva SR, Evans JR, Kirthi V, Ziaei M, Leyland M. Multifocal versus monofocal intraocular lenses after cataract extraction. Cochrane Database Syst Rev. 2016 Dec 12;12(12):CD003169. doi: 10.1002/14651858.CD003169.pub4.
Reference Type
BACKGROUND
Flockerzi E, Vinciguerra R, Belin MW, Vinciguerra P, Ambrosio R Jr, Seitz B. Combined biomechanical and tomographic keratoconus staging: Adding a biomechanical parameter to the ABCD keratoconus staging system. Acta Ophthalmol. 2022 Aug;100(5):e1135-e1142. doi: 10.1111/aos.15044. Epub 2021 Oct 16.
Reference Type
BACKGROUND
Vandevenne MMS, Webers VSC, Segers MHM, Berendschot TTJM, Zadok D, Dickman MM, Nuijts RMMA, Abulafia A. Accuracy of intraocular lens calculations in eyes with keratoconus. J Cataract Refract Surg. 2023 Mar 1;49(3):229-233. doi: 10.1097/j.jcrs.0000000000001088. Epub 2022 Oct 28.
Reference Type
BACKGROUND
Haigis W. Challenges and approaches in modern biometry and IOL calculation. Saudi J Ophthalmol. 2012 Jan;26(1):7-12. doi: 10.1016/j.sjopt.2011.11.007.
Reference Type
BACKGROUND
Hashemi H, Heydarian S, Hooshmand E, Saatchi M, Yekta A, Aghamirsalim M, Valadkhan M, Mortazavi M, Hashemi A, Khabazkhoob M. The Prevalence and Risk Factors for Keratoconus: A Systematic Review and Meta-Analysis. Cornea. 2020 Feb;39(2):263-270. doi: 10.1097/ICO.0000000000002150.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
prot. n. 22546
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
NCT05821101
ACTIVE_NOT_RECRUITING
NA
Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye
NCT04482439
COMPLETED
NA
Performance of Two Intraocular Lenses With Extended Depth of Vision
NCT05194150
UNKNOWN
NA
Visual Results of the Acrysof IQ Vivity Toric Extended Vision Intraocular Lens
NCT04652037
COMPLETED
NA
A Clinical Study of the ACRYSOF® IQ EDF Intraocular Lens (IOL)
NCT03010254
COMPLETED
NA
Evaluation of Visual Function After Bilateral Implantation of EDOF IOLs
NCT05335408
COMPLETED
NA
Tolerance to Residual Astigmatism in Eyes With Vivity®
NCT05392998
COMPLETED
Vivity IOL: Emmetropia Compared to Monovision.
NCT05464732
COMPLETED
NA
Myopic Monovision: EDOF vs. Monofocal IOL
NCT05194670
UNKNOWN
NA
Non-comparative Study to Assess the Visual Performances and Safety of a Progressive Multifocal Intraocular Lens
NCT02838004
COMPLETED
NA
A Comparative Study of Visual Outcome of Two Extended Depth of Focus Intraocular Lenses After Cataract Surgery
NCT05647421
UNKNOWN
NA
Bilateral Monofocal Versus Monofocal-EDOF IOL Implantation: Quality of Vision Comparison
NCT06002399
NOT_YET_RECRUITING
NA
Comparison of Two Non- Diffractive Extended Depth of Focus Intraocular Lenses
NCT06607848
RECRUITING
NA
Visual Outcomes and Patient Satisfaction After Bilateral Implantation of Non-diffractive EDOF IOL Made of a New Hydrophobic Acrylic Material
NCT05488769
TERMINATED
Visual Quality and Performance of Eyes With Asqelio™ EDoF Toric Lenses
NCT06707545
COMPLETED
Clinical Comparison of a Monofocal eDOF IOL With a Monofocal IOL
NCT04631068
COMPLETED
NA
EDOF and Multifocal IOL Study
NCT05573529
COMPLETED
NA
Single-center, Double-arm, Prospective Clinical Trial to Compare Visual Performance of Non-diffractive Extended Vision and Neutral Aspheric Monofocal Intraocular Lenses
NCT04591054
COMPLETED
NA
Visual Outcomes of Vivity in Patients With High Axial Length
NCT05210569
COMPLETED
Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control
NCT04561570
COMPLETED
PMCF Study on EDOF (Isopure) vs Monofocal (Micropure) IOL
NCT04249492
COMPLETED
NA
The Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus
NCT02740010
COMPLETED
Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
NCT06784063
COMPLETED
NA
Intraindividual Comparison of EMO IOLs
NCT05822089
RECRUITING
NA